

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1993PLC056594

Ref: **STEX/OUTCOME/2020-21**

Date: **13.11.2020**

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the half year ended on September 30, 2020.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the half year ended on September 30, 2020 as **Annexure-A** and
- b) Limited Review Report on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- c) An Investor Release on the financial results is enclosed at **Annexure-C**.

The meeting of the Board of Directors commenced 1.00 p.m. and concluded at 3.15 p.m.


The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the half year ended on September 30, 2020, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com


Unaudited Standalone and Consolidated Financial Results for the quarter and Half Year ended on 30th Sep' 2020

PART I	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		3 Months Ended 30.09.2020	Preceding 3 Months Ended 30.06.2020	Corresponding 3 Months Ended 30.09.2019	30th Sep' 2020	30th Sep' 2019	31.03.2020	3 Months Ended 30.09.2020	Preceding 3 Months Ended 30.06.2020	Corresponding 3 Months Ended 30.09.2019	30th Sep' 2020	30th Sep' 2019	31.03.2020
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
1	Income from operations												
	(a) Net Sales / Income from operations	3,077.19	2,611.52	3,551.51	5,688.71	6,664.42	11,734.23	3,077.19	2,778.35	3,551.51	5,855.54	6,664.42	12,550.38
	(b) Other Income	13.19	8.41	35.30	21.60	39.14	190.86	13.19	8.41	35.30	21.60	39.14	193.88
	(c) Total Revenue	3,090.38	2,619.93	3,586.81	5,710.31	6,703.56	11,925.09	3,090.38	2,786.76	3,586.81	5,877.14	6,703.56	12,744.26
2	Expenses												
	a) Cost of Material Consumed	1,910.12	1,657.04	2,190.67	3,567.16	4,344.74	7,449.16	1,910.12	1,798.17	2,190.67	3,708.29	4,344.74	8,045.29
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	7.62	38.10	73.98	45.72	4.23	(153.25)	7.62	38.10	73.98	45.72	4.23	(153.25)
	d) Employees Benefits Expenses	216.57	216.21	243.85	432.79	442.01	929.43	216.57	219.93	243.85	436.50	442.01	952.38
	e) Finance Cost	37.77	23.95	21.36	61.72	37.75	56.85	37.77	23.95	21.36	61.72	37.75	56.85
	f) Depreciation and Amortisation Expenses	69.85	69.24	62.37	139.09	119.33	249.92	69.85	69.24	62.37	139.09	119.33	249.92
	g) Other expenses	388.43	310.11	472.65	698.54	801.80	1,732.59	388.43	319.54	472.65	701.97	801.80	1,795.05
	Total Expenses	2,690.36	2,314.66	3,064.88	4,945.02	5,749.88	10,264.71	2,690.36	2,462.93	3,064.88	5,093.29	5,749.88	10,946.24
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	460.02	305.27	521.93	765.29	953.70	1,660.39	460.02	323.83	521.93	783.85	953.70	1,798.02
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax	460.02	305.27	521.93	765.29	953.70	1,660.39	460.02	323.83	521.93	783.85	953.70	1,798.02
6	Tax Expenses												
	Current Year	135.97	92.30	150.18	228.27	261.18	459.52	135.97	96.94	150.18	232.91	261.18	493.93
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	1.69	2.48	(11.97)	4.17	(19.39)	(25.03)	1.69	2.48	(11.97)	4.17	(19.39)	(25.03)
	Total Tax Expense	137.66	94.78	138.21	232.44	241.85	434.49	137.66	99.41	138.21	237.08	241.85	468.90
7	Net Profit / Loss for the period from Continuing operation (5 - 6)	322.36	210.49	383.72	532.85	711.85	1,225.89	322.36	224.42	383.72	546.77	711.85	1,329.12
8	Other Comprehensive Income												
	Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	322.36	210.49	383.72	532.85	711.85	1,225.89	322.36	224.42	383.72	546.77	711.85	1,329.12
10	Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66
11	Earning Per Share (Rs.)												
	Basic	2.64	1.72	3.18	4.36	5.89	10.09	2.64	1.84	3.18	4.48	5.89	10.94
	Diluted	2.64	1.72	3.18	4.36	5.89	10.09	2.64	1.84	3.18	4.48	5.89	10.94

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 13th November 2020.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- Limited Review Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 13.11.2020

For & on behalf of Board of Directors
Medicamen Biotech Limited

(Rahul Bishnoi)
Chairman

STATEMENT OF ASSETS & LIABILITIES				
All Figures in Rs. Lacs				
Particulars	Standalone		Consolidated	
	As at Sep 30,2020 Un-audited	As at Mar 31,2020 Audited	As at Sep 30,2020 Un-audited	As at Mar 31,2020 Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	3,558.85	3,342.53	3,558.85	3,342.54
(b) Intangible assets	23.66	26.91	23.66	26.91
(c) Capital work-in-progress	4,683.63	4,049.57	4,683.63	4,049.57
(d) Financial Assets : Investments	206.14	206.14	-	-
(e) Financial Assets : Loans and advances	62.73	62.73	62.73	62.73
(f) Other Non- current assets	446.54	233.41	446.54	233.41
Total Non-current Assets	8,981.54	7,921.29	8,775.40	7,715.16
2 Current assets				
(a) Inventories	786.85	1,695.75	786.85	1,695.75
(b) Financial Assets				
(i) Current investments	-	-		
(ii) Trade receivables	4,647.26	4,393.01	5,282.92	4,995.82
(iii) Cash and Bank Balances	302.53	223.32	316.44	309.28
(iv) Loans and advances	465.38	857.69	465.38	857.69
(c) Other current assets	2,836.62	2,554.57	2,836.62	2,554.57
Total current Assets	9,038.64	9,724.34	9,688.21	10,413.11
Total Assets	18,020.18	17,645.63	18,463.61	18,128.27
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity share capital	1,221.66	1,221.66	1,221.66	1,221.66
(b) Other Equity	11,558.90	11,026.07	11,456.24	10,899.96
Total Equity	12,780.56	12,247.73	12,677.90	12,121.62
LIBILITIES				
2 Non-current Liabilities				
(a) Financial Liabilities : Borrowings	712.88	235.85	712.88	235.85
(b) Provisions	172.44	106.03	172.44	106.03
(c) Deferred Tax liabilities (Net)	20.57	16.40	20.57	16.40
Total Non-current Liabilities	905.89	358.28	905.89	358.28
3 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	1,121.19	761.57	1,121.19	761.57
(ii) Trade payables	2,386.03	3,195.71	2,850.70	3,738.11
(b) Other current liabilities	598.23	559.46	636.51	591.41
(c) Provisions	228.27	522.88	271.42	557.28
	4,333.72	5,039.62	4,879.82	5,648.37
Total Equity and Liabilities	18,020.18	17,645.63	18,463.61	18,128.27

For & on behalf of Board of Directors
 Medicamen Biotech Limited


 (Rahul Bishnoi)
 Chairman

Place : Delhi
 Dated : 13.11.2020

MEDICAMEN BIOTECH LIMITED
 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
 CIN : L74899DL 1993PLC056594

CASH FLOW STATEMENT FOR THE PERIOD 01.04.2020 TO 30.09.2020

Particulars	All Figures in Rs. Lacs			
	STANDALONE		CONSOLIDATED	
	Half Year ended 30th Sep, 2020	For the year ended 31st March, 2020	Half Year ended 30th Sep, 2020	For the year ended 31st March, 2020
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit/(Loss) after tax from continuing operations	532.85	514.05	546.77	617.28
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	228.27	198.34	232.91	232.75
Depreciation/amortization on continuing operation	139.09	130.59	139.09	130.59
Loss/(profit) on sale of fixed assets	-	0.42	-	0.42
Interest expense	61.72	19.10	61.72	19.10
Interest income	(1.70)	(41.60)	(1.70)	(41.60)
Adjustment for Deferred Tax	4.17	(5.70)	4.17	(5.70)
Operating profit before working capital changes	964.40	815.20	982.96	952.84
MOVEMENTS IN WORKING CAPITAL:				
Increase/(decrease) in trade payables	(809.68)	(143.67)	(887.41)	398.73
Increase / (decrease) in long-term provisions	66.41	4.91	66.41	4.91
Increase / (decrease) in short-term provisions	(66.33)	(197.83)	(52.95)	(197.83)
Increase/(decrease) in other current liabilities	22.07	268.13	28.64	300.07
Decrease/(increase) in trade receivables	(254.25)	1,332.67	(287.10)	729.86
Decrease/(increase) in inventories	908.90	(414.50)	908.90	(414.50)
Decrease / (increase) in long-term loans and advances	0.00	(0.01)	(0.00)	(0.01)
Decrease / (increase) in short-term loans and advances	392.31	451.05	392.31	451.05
Decrease/(increase) in other current assets	(474.03)	(341.15)	(474.03)	(341.15)
Decrease/(increase) in other Non-current assets	(213.13)	(98.19)	(213.13)	(98.19)
Direct taxes paid (net of refunds)	(191.98)	(295.00)	(191.98)	(295.00)
Net cash flow from/ (used in) operating activities (A)	344.70	1,381.61	272.63	1,490.77
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of fixed assets, including intangible assets and CWIP	(986.22)	(1,976.08)	(986.21)	(1,976.08)
Purchase of non-current investments	-	(206.14)	-	-
Interest received	1.70	41.60	1.70	41.60
Net cash flow from/(used in) investing activities (B)	(984.51)	(2,140.62)	(984.50)	(1,934.48)
CASH FLOWS FROM FINANCING ACTIVITIES :				
Proceeds from issuance of share capital	-	-	-	-
Proceeds from Securities Premium	-	-	-	(229.33)
Capital Reserve	-	-	-	-
Shares Warrants	-	-	-	-
Long-term borrowings net of repayment / Repayment of Long Term Borrowings	477.03	227.65	477.04	227.65
Proceeds from short-term borrowings	359.62	245.89	359.62	245.89
Interest paid	(61.72)	(19.10)	(61.72)	(19.10)
Dividends paid on equity shares	(55.91)	-	(55.91)	-
Tax on equity dividend paid	-	-	-	-
Net cash flow from/(used in) financing activities (C)	719.02	454.44	719.02	225.11
Net increase/(decrease) in cash and cash equivalents (A + B + C)	79.21	(304.57)	7.15	(218.60)
Cash and cash equivalents at the beginning of the year	223.32	527.89	309.29	527.89
Cash and cash equivalents at the end of the year	302.53	223.32	316.44	309.29

For & on behalf of Board of Directors
 Medicamen Biotech Limited



R. Bishnoi
 (Rahul Bishnoi)
 Chairman

Place : Delhi
 Dated : 13.11.2020



Independent Auditor's Review Report on Standalone Half Yearly Financial Results

To

The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43,
Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended September 30, 2020 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Gurugram
Date: 13.11.2020

For Rai Qimat & Associates
Chartered Accountants


CA Qimat Rai Garg
(Partner)

(FRM No.: 013152C)

UDIN:-20080857AAAACH9109




Independent Auditor's Review Report on Consolidated Unaudited Quarterly & Half Yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors,
Medicamen Biotech Limited**
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019


1. We have reviewed the Unaudited Consolidated Financial Results of Medicamen Biotech Limited (the "Parent Company"), and the Subsidiary Company for the quarter & half year ended on September 30, 2020 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter & half year ended on September 30, 2020 (the "Statement")'. The Statement is being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd (the "Subsidiary" Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Consolidated Unaudited Financial Results also includes the Group's share of net profit after tax of Rs. 13.92 Lakhs for the half year ended September 30, 2020, as considered in the consolidated unaudited financial results, in respect of a subsidiary, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Place: Gurugram
Date: 13.11.2020

For Rai Qimat & Associates
Chartered Accountants


CA Qimat Rai Garg
(Partner)

(FRM No.: 013152C)

UDIN:-20080857AAAACH9109



Investor Presentation Sept 2020

Medicamen Biotech Limited



Committed for **affordable quality healthcare** and aiming leadership through continual improvement and technology

Safe Harbour Statement

This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements. These factors include, but are not limited to, domestic and global economic and business conditions, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, etc. As a result, MBL’s actual future results may differ materially from the plans, goals and expectations set forth in such forward looking statements. MBL does not undertake any obligation to update such forward looking statements to reflect events or circumstances after the date thereof.

Overview



Business Area

- Vertically integrated pharmaceutical company with presence across geographies – India, Latin America, Africa & rest of world (ROW)
- Developing, manufacturing and marketing of finished dosages across wide range of therapeutic domains
- Strong focus on R&D with over 45 employees dedicated to R&D
- **New Oncology formulation plant at Haridwar got manufacturing/drug license from Drug Controlling & Licensing Authority, Uttarakhand**

Subsidiary

- In Australia, strong portfolio with 14 products

Production site

Three Manufacturing state of the art facilities


- 2 General facility in Bhiwadi & Haridwar
- 1 Oncology facility in Haridwar

Certification


- Certified by WHO, ANVISA (Brazil), NAFDAC, MCAZ and DACAetc

Overall Snapshot


Quarterly Revenue and Growth



Quarterly PAT margin and Growth %



Quarterly EBITDA margin and Growth %



Due to Covid-19, top line & bottom Line have been impacted during the current quarter otherwise gross margins, EBITDA & PAT all on uptrend

Overall Snapshot (Quarterly)

INR Lacs	Q2'FY21	Q1'FY21	Q2'FY20
Revenue from Operations	3,077	2,612	3,551
Other Income	13	8	35
Total Income	3,090	2,620	3,586
COGS	1,918	1,696	2,264
Employee Benefit Expenses	217	216	244
Finance Costs	38	24	21
Depreciation	69	69	62
Other Expenses	388	310	473
Total Expenses	2,630	2,315	3,064
Profit Before Tax	460	305	522
Tax	138	95	138
Profit After Tax	322	210	384

Manufacturing facilities of Medicamen Biotech

Bhiwadi Plant Location: Rajasthan		Haridwar Plant (Unit I) Location: Utrakhand		Haridwar Plant (Unit II) Location: Utrakhand	
Facility divided into six separate blocks		Facility has a single three-storied unit		Dedicated plant to manufacture oncology products	
Beta Lactum Block	<ul style="list-style-type: none"> ▪ Tablets ▪ Capsules ▪ Dry syrups 	Non Betalactum Tablets		Tablets	
Non-Beta Lactum Block	<ul style="list-style-type: none"> ▪ Tablets ▪ Capsules ▪ Dry syrups 	Non-Betalactum Capsules	<ul style="list-style-type: none"> ▪ Liquid orals ▪ External ointments 	Capsules	
ORS and Liquid Orals Block				Injectables	
Warehouse and Quality Assurance / Quality Control Block				Lyophilizers	
Formulation Development, Analytical and Chemical Research Development				US-FDA and EU compliant facility with state-of-the-art plant and machinery	
Finished Goods Store Block					

Manufacturing facilities of Medicamen Biotech



**Bhiwadi
Plant**

Covered area: 120,000 square feet
General pharmaceutical formulation
division



**Haridwar Plant
(Unit I)**

Covered area: 32,000 square feet
General pharmaceutical formulation
division



**Haridwar Plant
(Unit II)**

Covered area: 35,000 square
feet Oncology formulation
division

Global presence



ESTABLISHED ONCOLOGY PLANT AT HARIDWAR




- Established State-of-the-art- Oncology Plant at Haridwar, machine validations are underway.
- Company expect to start Plant Validation batches for ANDA filing by Dec'20.
- Company expect to file 2 ANDA by July'21.
- Drug licence already granted.

Rationale for oncology product selection



Robust R&D Capabilities



Strength of R&D ~ 45 employees


- State-of-art R&D set up duly approved from Department of Scientific and Industrial Research (DSIR), Govt of India
- Development facility at **Bhiwadi** for development of Active Pharma Ingredients (API) and Intermediates along with Formulations R&D.
- Backed by the team of highly professional and well-experienced team of researchers and scientist for development of new products.

Bhiwadi Plant





New Oncology Plant - Haridwar



Thank you!

Medicamen Biotech Limited

REGISTERED OFFICE

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019

Phone 011-47589500 (30 Lines) | **Fax** 011-26213081 | **E-mail** cs@medicamen.com

Website www.medicamen.com